doi: 10.3109/10428194.2010.551572.
Epub 2011 Jan 27.
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans
Affiliations
- PMID: 21271864
- PMCID: PMC3138221
- DOI: 10.3109/10428194.2010.551572
Item in Clipboard
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans
Leuk Lymphoma.
2011 May.
Abstract
Survival is reportedly worse in patients with cancer concurrently diagnosed with deep venous thrombosis. However, information on specific malignancies is limited. From a cohort study of male US veterans we identified incident cancer cases (n = 412,008) and compared survival patterns among those with versus without a history of deep venous thrombosis. Using Cox proportional hazard models, we estimated hazard ratios (HRs) and 95% confidence intervals as measures of the relative risk of dying. Individuals with (versus without) a concomitant deep venous thrombosis and cancer diagnosis had a higher risk of dying (HR = 1.38; 1.28-1.49). The most prominent excess mortality (HR = 1.29-2.55) was observed among patients diagnosed with deep venous thrombosis at the time of diagnosis of lung, gastric, prostate, bladder, or kidney cancer. Increased risk of dying was also found among cancer patients diagnosed with deep venous thrombosis 1 year (HR = 1.14; 1.07-1.22), 1-5 years (HR = 1.14; 1.10-1.19), and >5 years (HR = 1.27; 1.23-1.31) before cancer; this was true for most cancer sites (HR = 1.17-1.64). In summary, antecedent deep venous thrombosis confers a worse prognosis upon cancer patients. Advanced stage at diagnosis, treatment effects, lifestyle factors, and comorbidity could explain differences by cancer site and time frame between a prior deep venous thrombosis diagnosis and cancer outcome.
Conflict of interest statement
Figures
A: Survival curves for all cancer patients with and without a history of deep venous thrombosis of the lower extremities (DVT). Adjusted survival curves are presented. The solid line represents cancer patients with no history of DVT. The dashed lines represent cancer patients with: DVT more than 5 years prior to cancer diagnosis (
), DVT 1–5 years before cancer diagnosis (
), DVT 1 year before cancer diagnosis (
) and DVT at cancer diagnosis (
). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
A: Survival curves for all cancer patients with and without a history of deep venous thrombosis of the lower extremities (DVT). Adjusted survival curves are presented. The solid line represents cancer patients with no history of DVT. The dashed lines represent cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
A: Survival curves for all cancer patients with and without a history of deep venous thrombosis of the lower extremities (DVT). Adjusted survival curves are presented. The solid line represents cancer patients with no history of DVT. The dashed lines represent cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
A: Survival curves for all cancer patients with and without a history of deep venous thrombosis of the lower extremities (DVT). Adjusted survival curves are presented. The solid line represents cancer patients with no history of DVT. The dashed lines represent cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.
), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). The lines for DVT 1–5 years before cancer diagnosis and DVT 1 year before cancer diagnosis are superimposed. P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. B: Survival curves for lung cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents lung cancer patients with no history of DVT. The dashed lines represent lung cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. C: Survival curves for colorectal cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents colorectal cancer patients with no history of DVT. The dashed lines represent colorectal cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (). P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001. D: Survival curves for prostate cancer patients with, and without, a history of deep venous thrombosis (DVT). Adjusted survival curves are presented. The solid line represents prostate cancer patients with no family of DVT. The dashed lines represent prostate cancer patients with: DVT more than 5 years prior to cancer diagnosis (), DVT 1–5 years before cancer diagnosis (), DVT 1 year before cancer diagnosis () and DVT at cancer diagnosis (P-value (likelihood ratio test) for difference in survival according to pre-existing DVT status: P<0.0001.Comment in
-
The association of cancer and venous thrombosis: yes, Trousseau is right...again!Leuk Lymphoma. 2011 May;52(5):734-5. doi: 10.3109/10428194.2011.560311. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463126 No abstract available.
Similar articles
-
Association of Short-Term Mortality of Venous Thromboembolism with Family History of Venous Thromboembolism and Charlson Comorbidity Index.Thromb Haemost. 2019 Jan;119(1):48-55. doi: 10.1055/s-0038-1676347. Epub 2018 Dec 31. Thromb Haemost. 2019. PMID: 30597499
-
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.Am J Med. 2004 Jul 1;117(1):19-25. doi: 10.1016/j.amjmed.2004.01.018. Am J Med. 2004. PMID: 15210384
-
Relationship between the site of thrombosis and the prevalence of pulmonary embolism in acute lower extremity deep venous thrombosis.J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):725-733. doi: 10.1016/j.jvsv.2019.11.010. Epub 2020 Feb 14. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32063525
-
The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update.Semin Thromb Hemost. 2019 Jun;45(4):321-325. doi: 10.1055/s-0039-1688494. Epub 2019 Apr 30. Semin Thromb Hemost. 2019. PMID: 31041801 Review.
-
[Venous thromboembolism and cancer].Rev Med Interne. 2006 Apr;27(4):313-22. doi: 10.1016/j.revmed.2005.11.016. Epub 2005 Dec 29. Rev Med Interne. 2006. PMID: 16414153 Review. French.
Cited by
-
Risk Factors for Gastric Cancer-Associated Thrombotic Diseases in a Han Chinese Population.Biomed Res Int. 2021 May 21;2021:5544188. doi: 10.1155/2021/5544188. eCollection 2021. Biomed Res Int. 2021. PMID: 34095299 Free PMC article.
-
Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma.J Gastrointest Cancer. 2018 Sep;49(3):275-282. doi: 10.1007/s12029-017-9945-6. J Gastrointest Cancer. 2018. PMID: 28374272
-
Primary urinary bladder adenosquamous carcinoma complicated with lower limb deep venous thromboses: a case report.Int J Clin Exp Pathol. 2014 Dec 1;7(12):9032-7. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25674283 Free PMC article.
-
Preoperative thrombocytopenia as a predictor of cancer-associated thromboembolism in gastric cancer patients undergoing gastrectomy.Front Oncol. 2025 Jul 16;15:1585201. doi: 10.3389/fonc.2025.1585201. eCollection 2025. Front Oncol. 2025. PMID: 40740872 Free PMC article.
-
Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer.Lung Cancer. 2014 Dec;86(3):358-62. doi: 10.1016/j.lungcan.2014.10.003. Epub 2014 Oct 12. Lung Cancer. 2014. PMID: 25453848 Free PMC article.
References
-
- Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005;95:1525–1526. - PubMed
-
- Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10(2):499–530. - PubMed
-
- Donati MB. Cancer and thrombosis. Haemostasis. 1994;24(2):128–131. - PubMed
-
- White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782–1787. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
